Improving African American Glaucoma Patient Involvement in Visits and Outcomes
- Conditions
- Glaucoma
- Registration Number
- NCT03657147
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Brief Summary
This is a research project about services provided to African American patients with glaucoma. The goal of the project is to improve communication between providers and African-American patients about glaucoma.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 189
- African American
- Age 18 or older
- Able to speak and read English
- Mentally competent to participate
- Not blind (are at least 20/400 in their better seeing eye)
- On one or more glaucoma medications
- Report being less than 80% adherent to their glaucoma medications on a Visual Analog Scale
- < 18 years of age
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Intraocular Pressure 12 months Intraocular pressure measurements will be extracted from each patient's medical record at the baseline, 6 month, and 12 month follow-up visits. For all time points, a mean intraocular pressure will be calculated by averaging the intraocular pressure across both eyes. Change in intraocular pressure over the 12 month period will then be assessed by calculating the difference in mean intraocular pressure.
Glaucoma Medication Percent Adherence 12 months Medication adherence will be measured using the number of recorded doses from the Medication Event Monitoring System (MEMS) data, divided by the number of prescribed doses. Medication adherence can range from 0% to 100%.
Glaucoma Medication Adherence Self-Efficacy Score 12 months Medication adherence self-efficacy is measured using a 21-item scale that has a reliability of 0.89. Scores can range from 21 to 63, and a higher score indicates a better outcome.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
University of North Carolina at Chapel Hill
🇺🇸Chapel Hill, North Carolina, United States
University of North Carolina at Chapel Hill🇺🇸Chapel Hill, North Carolina, United States